The bi‐EGF‐IT has an increased binding affinity in vitro and is more effective and less toxic at inhibiting primary HNSCC tumor growth and metastasis in vivo compared with mono‐EGF‐IT, representing a promising EGFR‐targeted drug candidate for HNSCC treatment. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.